Overview Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients Status: Completed Trial end date: 2017-05-01 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the safety/tolerability and to explore the efficacy of MT-1303 in subjects with systemic lupus erythematosus Phase: Phase 1 Details Lead Sponsor: Mitsubishi Tanabe Pharma Corporation